To investigate the effect of low doses of IL-2 in combination with hI-con1 (30 μg/ml) on IDCC against primary cervical cancer cell lines, PBL from healthy donors were incubated for 5 hours in the presence of 50 to 100 IU/ml of IL-2. The gene discussed is IL2; the disease is cervical carcinoma.